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Abstract
Post-translational modifications play an essential role in regulating protein
structure and function. Enzymes catalyzing these modifications must often
recognize and modify multiple substrate proteins from among a plethora of nonsubstrates with similar structures and amino acid sequences. For example, protein
farnesyltransferase (FTase) catalyzes the addition of an isoprenoid group to a
cysteine near the C-terminus of a substrate protein and is proposed to modify a
pool of substrates numbering more than one hundred. We seek to understand the
interactions in the FTase active site that engender substrate selectivity. By
mutating two residues within FTase, we have developed FTase variants with
expanded substrate selectivity. The alteration in substrate selectivity observed in
our variants suggests that FTase selectivity may depend on a small number of
“tunable” active site contacts. Our work provides insight into how this
multispecific enzyme recognizes its pool of substrates and will also aid in
identifying additional FTase substrates.
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Introduction

Protein prenylation is an important posttranslational modification required for
the proper localization and function of many eukaryotic proteins (6). Prenylated
proteins are involved in vital cell signaling transduction pathways that control cell
growth and differentiation, with these proteins linked to diseases including cancer
and cardiovascular disease (10). Understanding how protein prenylation affects
cellular health requires us to identify which proteins are prenylated and then
characterize the impact of prenylation pathwaymodifications on protein structure
and function.
Protein farnesyltransferase (FTase) is a heterodimeric enzyme that catalyzes the
addition of a fifteen-carbon prenyl group to the cysteine of the “Ca1a2X” Cterminal sequence of a substrate protein,
the first step in the prenylation pathway
(Figure 1). This prenyl group increases
the hydrophobicity of the protein and
aids in localizing the peptide to cellular
membranes (1) FTase readily
prenylates a range of Ca1a2X sequences,
but the interactions that lead to
selectivity within the Ca1a2X sequence
are still not well defined (2-5, 11). A
2009 study by Hougland and coworkers

Fig 1. Prenylation pathway
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suggests that the hydrophobicity and steric volume of the a2 residue serve as
determinants of peptide selectivity by
FTase (6).
In addition to understanding what
properties within the protein substrate
are recognized by FTase, we must also
identify the amino acids within the
FTase active site that transduce these
interactions involved in substrate
selectivity. Both structural and
biochemical studies indicate that tthe

Fig 2. Interaction of a2 with the W102β
W102
(orange) and W106β
β (red) residues of
wildtype FTase. The lipid tail of a FPP
analogue (purple) is also shown here to
contact the a2 residue. Figure
Fi
from ref 6.

W102β and W106β residues within the active site of FTase play the key roles in
recognizing the a2 residue (Figure 2) (2, 7). Mutation of these two residues has
also been demonstrated to alter FTase substrate selectivity, thereby revealing the
“tunable” nature of substrate selectivity in FTase (7).
To explore more fully the potential for altering FTase substrate selectivity
through mutation of two active site residues, we developed a library of ~400
FTase variants using a previously generated FTase plasmid library wherein the
codons for the two active site amino acids, W102β and W106β,
β, have been
randomized. A subset of these variants were screened for prenylation activity with
three target peptides, CVDS, CVYS, and CVGS, that bear Ca1a2X sequences that
are markedly less reactive with FTase than “natural” substrates such as H-Ras (GCVLS).. Using a fluorescence
fluorescence-based
based assay that probes prenyltransferase activity
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in bacterial cell lysates, we isolated two variant FTases from among the screened
variants that exhibited prenylation activity with the CVYS target peptide. These
two variants were then expressed, purified, and their enzymatic activity
characterized under steady state conditions. Unexpectedly, we also observed and
characterized the resistance of these two variants to the highly selective and
potent FTase inhibitor, FPTII.
These studies provide a deeper understanding of the interactions that engender
a2 selectivity in FTase and promote the development of FTase variants that will
serve as tools for studying prenylation pathway modifications within the cell. In
addition, the characterization of FTase substrate recognition derived from my
research will also provide insight for the development of better FTase inhibitors,
an active area of drug research that is currently hindered in part because the
specific protein targets of FTase are unknown (8, 12).
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MATERIALS AND METHODS
Preparation of W102β and W106β FTase variant library. A previously
generated variant FTase plasmid library with mutations at W102β and W106β in
the context of the pET23aPFT vector was utilized to generate the FTase variant
libraries described herein (7). Codons for positions 102β and 106β have been
randomized using an NNK codon (N = equal mixture of A, T, C, and G, K = G or
T). To generate a library of FTase variants, 24 ng (3 µL of 8 ng/µL) of the variant
FTase plasmid DNA was transformed into each of four 100 µL aliquots of Zcompetent BL21(DE3) E. coli cells (73.4 ng/µL). A plasmid for wild-type FTase
(21.4 ng) was also transformed into a 100 uL aliquot of Z-competent BL21(DE3)
E. coli cells. The cells were plated onto LB agar plates containing 100 µg/mL
ampicillin and grown overnight (~ 16 hours).
Following overnight incubation, 376 single colonies were inoculated into single
wells of four 96-well (2.2 mL well volume) growth plates using sterile toothpicks.
Each well contained 900 µL of filter sterilized (0.22 µm) growth media composed
of LB media, 1% glucose, 100 µg/mL ampicillin and 60 µM isopropyl β-D-1thiogalactopyranoside (IPTG). Each of the four 96-well plates contained a well
inoculated with one colony transformed with wild-type FTase to serve as a
positive control, a well inoculated with one colony transformed with an empty
pET23a vector to serve as a negative control, and 94 wells inoculated with
colonies transformed with variants. The four plates were labeled Cultures 1 – 4,
sealed with gas-permeable adhesive seals, and incubated with shaking (400 RPM)
for 16 hours at 28°C. Following incubation, cultures 2- 4 were sealed and stored
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at -80°C. Glycerol stocks for variants in the Culture 1 plate were prepared by
aliquoting 50 µL of culture from each well into another growth plate with 450 µL
of LB with 100 µg/mL ampicillin in each well. Following incubation with shaking
(400 RPM) for 16 hours at 28°C, the cultures in each well was mixed with 500 µL
of 20% sterile glycerol. The resulting glycerol stock was stored at -80°C.
Screening of FTase variants. Cultures in each well of the Culture 1 plate were
lysed using 100 µL of cell lysis reagent per well. The cell lysis reagent consists of
9.6 mL Fast Break cell lysis reagent (Promega), 4.8 µL benzonase (125 U/mL), 1
mL lysozyme (20 mg/mL in purified water) and 384 µL
phenylmethanesulfunylfluoride (PMSF, 5 mg/mL in ethanol), with PMSF added
last. Following addition of 100 µL of cell lysis reagent per well to the Culture 1
plate, the plate was shaken (380 rpm) for 20 minutes at 28°Cand then stored on
ice until used in screening assays.
A steady-state kinetics fluorescence assay was used to screen for FTase variants
capable of farnesylating selected dansylated peptides. Farnesylation of dansylated
peptides was monitored by fluorescence using a POLARstar Galaxy plate reader
(λex 340 nm, λem 520 nm) for 4 hours. Farnesylation of the dansylated peptides
leads to an increase in fluorescence of the dansyl fluorophore, (9) providing a
signal for peptide prenylation. Screening reactions for FTase variant activity with
target peptides were as follows, with reactions run at room temperature: 3 µM
dansylated peptide, 5 µL cell lysate, 10 µM farnesyl pyrophosphate (FPP), 50
mM HEPPSO pH 7.8, 5 mM tris(2-carboxyethyl)phosphine (TCEP), and 5 mM
MgCl2.
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Recent studies of in vivo protein prenylation in the Hougland Lab have
identified a set of peptide sequences with point mutations at the a2 residue that
appear to block prenylation by wild type FTase (S. Flynn, manuscript in
preparation). From among these sequences, CVDS, CVYS, and CVGS were
selected as initial targets for FTase variant selection. In addition to these three
target peptides, FTase variant activity reactions were run in parallel with the
“natural” substrate CVLS to determine if the FTase variants retain activity with a
positive control substrate.
For each screening reaction, a 96 well reaction plate was prepared for each
peptide substrate as follows; a typical set of screening reactions involved four 96
well plates. A reaction stock solution was prepared, consisting of 11.9 mL dH20, 2
mL of 10x reaction buffer (500 mM Heppso pH 7.8, 50 mM TCEP), 100 µL 5
mM MgCl2, and 4 mL 10 µM FPP. The stock solution (45 µL) was aliquoted into
each well of the 96 well reaction plates. Cell lysate (5 µL) from each well of the
Culture 1 growth plates was transferred into its corresponding well in each of the
four reaction plates (lysate from well A01 was added to well A01 of reaction
plates 1,2,3 and 4, lysate from well A02 was added to well A02 of reaction plates
1,2,3 and 4, etc.) Reactions were initiated by the addition of 50 µL of a 6 µM
peptide stock into each well. Each reaction plate was initiated by a different
peptide (reaction plate 1 with dansyl- GCVLS, reaction plate 2 with dansylGCVYS, etc.)
Fluorescence was measured at 12 time points (0 min, 10 min, 20 min, 30 min,
40 min, 50 min, 60 min, 90 min, 120 min, 150 min, 180 min and 240 min). The
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results were combined to determine the time dependence of the fluorescence
change for each variant with each peptide. Reactions whose variants who both
exhibited a minimum fluorescence change that is at least 70% of the maximum
change of wild-type FTase with dansyl-GCVLS (~2450 Au) and reached
completion (a plateau in fluorescence) within 2-fold of the time required for wildtype FTase with dansyl-GCVLS (~100 min) were considered active. Two active
variant FTases exhibiting prenylation activity with the CVYS target peptide
(Wells A05 and F03) were selected from this screen, sequenced, and purified.
Sequencing of Selected FTase Variants: The BL21(DE3) E. coli cells
containing the plasmids for the two selected variants were regrown from the
glycerol stock. For each variant, a minimal amount of frozen culture was
inoculated into a culture tube containing 5 mL 2xYT media supplemented with
2% glucose and 100 µg/mL ampicillin. The cells were incubated with shaking
(275 rpm) for 16 hours at 37°C. Following overnight culture, the plasmid
encoding the FTase variant was purified using the protocol for purification of low
copy plasmid DNA from the EZ-10 Spin Column Plasmid DNA MiniPrep Kit
(Bio Basic Inc). Plasmid concentrations were determined by UV-Vis spectroscopy
using the Nanodrop 2000c UV-Vis spectrometer, and the mutations at positions
102 and 106 were determined by DNA sequencing (Genewiz).
Purification of Selected FTase Variants. For each FTase variant, 1 µL of
plasmid (30.7 ng/µL for A05 and 92.7 ng/µL for F03) was transformed into a 100
uL aliquot of BL21-DE3 E. coli cells and plated on a LB agar plate containing
100 µg/mL ampicillin. Following overnight incubation, a single colony was
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inoculated into 5 mL 2xYT growth media with 100 µg/mL ampicillin and
incubated with shaking (225 rpm) at 37°C. After 5 hours incubation, the 5 mL
starter culture was inoculated into a 3 L baffled flask containing 1 L of sterile
autoinduction media (10 g tryptone, 5 g yeast extract, 872.5 mL of H2O (pH
adjusted to 7.45 with KOH), 25 mL 1M Na2HPO4, 25 mL 1M KH2PO4, 50 mL
1M NH4Cl, 5 mL 1M Na2SO4, 2 mL 1M MgSO4, 200 µL trace metals) with 100
µg/mL ampicillin and incubated with shaking (200 rpm) for 24 hours at 28°C.
Following incubation, cells were harvested by centrifugation (6000 rpm, 15
min, 4°C) and the pellet was re-suspended in 50 mL resuspension buffer (50 mM
HEPES pH 7.8, 10 µM ZnCl2, 2 mM TCEP, 17 µg/mL PMSF). Prior to lysis,
benzonase (7.875 µL/63mL), lysozyme (0.2 mg/mL) and PMSF (17 µg/mL) were
added to the cell suspension. After a 45 min. incubation period at 37°C, the cells
were lysed by sonication (8 x 30 seconds at 30 Watts, with 30 second rests
between cycles). Following sonication, cell debris was removed by centrifugation
(18000 x g, 45 min, 4°C). The supernatant was treated with 1/10 volume of 10%
streptomycin sulfate added drop wise in the cold room followed by stirring for 20
min at 4°C. The resulting solution was clarified by centrifugation (18000 x g, 45
min, 4°C), followed by filtration through a 0.45 µM syringe filter.
The filtered supernatant was loaded onto a HiTrap DEAE anion-exchange
column (3 x 5mL prepacked columns) washed with HTZ buffer (50 mL 1 M
Hepes pH 7.8, 4 mL 2.5 mM ZnCl2, 946 mL H2O and 0.6 g TCEP) and FTase was
eluted by a NaCl gradient (HTZ + 0.5 M NaCl buffer) per preprogrammed
gradient (AktaPrime, GE Healthsciences). Fractions containing FTase were

12

determined by SDS-PAGE analysis, collected, concentrated with 30K
concentrators (PALL MacroSep Advance Centrifugal Devices), and diluted to 10
mL with HZ buffer (HTZ buffer without TCEP). The partially purified FTase was
likewise purified using a HiTrapQ anion-exchange column (3 x 5mL prepacked
columns) using a NaCl gradient, concentrated to ~10 µM as determined by UV
absorbance at 280 nm (extinction coefficient 1.5 x 105 M-1cm-1) and stored in 25
uL aliquots at -80°C.
Active Site Titration of purified FTase Variants: The concentration of active
enzyme was determined by active site titration of the purified variants. .
Increasing concentrations (between 0 nM to 1000 nM) of the dansyl- CVLS and
dansyl - CVYS peptides were titrated into 100 µL solutions containing 300 nM
enzyme, 5 µM FPTII inhibitor, 1x FTase reaction buffer (50 mM Heppso pH 7.8,
5 mM TCEP) and 5 mM MgCl2. After the addition of peptide, the sample was
incubated in the dark for 10 minutes to allow peptide binding to reach completion
before a fluorescence (λex 280 nm, λem 496 nm) reading was obtained. Reactions
lacking enzyme were run in parallel as negative controls. The concentration of
enzyme active sites was calculated from the collected data by finding the
intersection of the linear slope lines for pre-saturated and saturated conditions of
the FTase-FPTII complex by dansylated peptide.
Steady-State Kinetics of Variant Enzymes. To measure the effects of the
mutations on the catalytic efficiency (kcat/KM) of FTase, the velocity for peptide
farnesylation at multiple peptide concentrations was determined using the
previously reported fluorescence-based assay (9). Increasing concentrations of
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dansyl- CVLS and dansyl - CVYS peptide (0.2 µM, 0.5 µM, 1 µM, 2 µM, 5 µM
and 10 µM) were titrated into 100 µL solutions containing 20 nM enzyme, 10 µM
FPP, 1x FTase reaction buffer and 5 mM MgCl2. Immediately after reaction
initiation by the addition of the enzyme stock, fluorescence was measured as a
function of time for 4 hours. KM was determined from Lineweaver-Burk plots; a
linear fit to the dependence of the inverse substrate concentration on inverse
initial velocity (eq 1). Initial velocity (V, µM/s) was determined by dividing the
linear velocity of the reaction in fluorescence units per second by an amplitude
conversion derived from an average of the total fluorescence change observed
upon reaction completion divided by the initial peptide substrate concentration.
kcat was derived from equation 2, where [E0] = enzyme concentration.
1/ = (KM/Vmax)(1/[s]) + 1/Vmax

(1)

Vmax = kcat[E0]

(2)

Testing of FPTII Inhibitor Resistance. To determine the effects of the
mutations on the affinity of FPTII inhibitor with FTase, increasing concentrations
of FPTII inhibitor (0 µM, 0.1 µM, 1.0 µM and 10 µM) were titrated into solutions
with 20 nM enzyme, 2 µM peptide, 1x FTase reaction buffer, 5 mM MgCl2 and
10 µM FPP. The velocity for peptide farnesylation in the presence of FPTII
concentrations was determined using the previously reported fluorescence-based
assay (9). The dissociation constant Ki of FPTII was determined from a fit of the
Michaelis-Menten equation adjusted for inhibition (eq 3) to the dependence of
initial velocity on FPTII concentration.
V=V0 * (1 




)



(3)
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KM values for FPP with the selected variants were also measured using the
fluorescence-based assay. Increasing concentrations of FPP (0.1 µM, 0.5 µM, 1
µM, 2 µM, 5 µM and 10 µM) were titrated into solutions with 15 nM enzyme, 2
µM dansyl-CVLS, 1x FTase reaction buffer and 5 mM MgCl2. Fluorescence (λex
340 nm, λem 520 nm) was monitored for four hours, and initial velocities were
measured as described above. KM of FPP was determined from a fit of the
Michaelis-Menten equation (eq 4) to the dependence of initial velocity on the FPP
concentration.
V=Vmax (







)



(4)
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Fig. 3: pCAF2 WW CVLS Vector
Mutagenesis of pCAF2 vectors. The shuttle vector pCAF was previously
modified to allow for co-expression of FTase and a florescent fusion protein (7).
In the vector pCAF2 WW CVLS (Figure 3), wild-type FTase was cloned into
open reading frame 1 (ORF1) and TagRFP-GCVLS into open reading frame 2
(ORF2). ORF1 is under the control of the CMV promoter while ORF2 is under
the control of the SV40 promoter. FTase variants were first introduced into the
pCAF2 WW CVLS plasmid by PCR site-directed mutagenesis. Mutations were
confirmed by DNA sequencing (GENEWIZ) using the CMV forward primer. The
TagRFP-CVYS mutation was then introduced into the pCAF variant CVLS
template and confirmed by sequencing using the SV40 reverse primer.
Cell culture, transfection, and imaging. HEK293T cells were cultured
in DMEM (Invitrogen) supplemented with 100 units/mL penicillin-streptomycin
16

and L-glutamine (2mM) and 10% fetal bovine serum (Complete Media). Cells
were maintained in a humidified atmosphere with 5% CO2 at 370C. HEK 293T
cells (4 x 104 cells) were plated in a 24 -well tissue culture treated plate (2.0 cm2
well size) and incubated for 24 and 48 hours. Cells were then transfected with 3µg
plasmid DNA using TurboFect (Fermenta) according to manufacturer’s protocols.
Following transfection for 48 hours, the cells were imaged using
a Zeiss Axio Vert A1 fluorescence microscope, with a minimum of 50 cells were
characterized and reported.
RESULTS
Selection of W102β and W106β mutants with increased reactivity with dansyl –
GCVYS. In the screening of novel FTase variants, 376 E. coli colonies derived
from the FTase plasmid library with double mutations at W102β and W106β were
selected to be assayed for farnesylation activity with peptide targets. Of the 94
variants screened, 31% (29/94 variants) exhibited high prenylation activity with
dansyl–GCVLS while 43% (40/94 variants) exhibited high prenylation activity
with dansyl –GCVYS. A variants is defined as exhibiting “high prenylation
activity” if the prenylation reaction with the target peptide satisfies two criteria: 1)
reaction completion within 2-fold of the time required for wildtype - FTase to
reach completion with its native substrate dansyl-GCVLS (~100min); and 2) a
minimum fluorescence change at least 70% of the maximum fluorescence change
observed for wildtype-FTase with dansyl-GCVLS (~2450 Au). The large pool of
variants that were able to prenylate the non-native substrate CVYS suggests that
substrate selectivity in FTase is easily altered and depends fundamentally on a
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small number of “tunable” active site contacts
contacts,, consistent with previous studies
(7).
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Fig 4.. Prenylation activity as observed by ∆ fluorescence
fluorescence (AU) with dansyldansyl
labeled peptides -GCVLS,
GCVLS, -GCVYS, -GCVDS, and -GCVGS
GCVGS with (A)
wildtype FTase, (B) W102Y W106L, and (C) W102F W106L
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Selected FTase variants Two variant FTases that exhibited high prenylation
activity with the CVYS target peptide as well as the native CVLS peptide (Figure
4) were isolated; these variants were sequenced and the mutations at W102β and
W106β are reported in Table 1. The kcat/KM values for these variants for reaction
with both the dansyl- CVLS and dansyl–CVYS peptides were calculated from
Lineweaver-Burk plots (Figure 5 and Table 2). Both the W102F W102L and
W102Y W106L mutants exhibit a ~100-fold increase in dansyl-GCVYS activity
when compared with wildtype-FTase. The mutants also simultaneously maintain
approximately the same level of activity
(within 2-fold) with dansyl-GCVLS as wildtype-FTase. These findings are
consistent with our earlier observations that the FTase active site is flexible and
that substrate selectivity can be easily modulated.
Table 1. Residues at position 102β and position 106β of wildtype and
selected variant FTases.

Well

Residue at position
102

Residue at position
106

WW FTase

W

W

A5

Y

L

F3

F

L

Table 2. The Kcat/KM values of wildtype FTase and the two variants (YL, FL)
with the peptides –GCCVLS and –GCVYS.

Enzyme

Kcat/KM (M-1s-1)
LS
1.7 x 105 ± 40

Kcat/KM (M-1s-1)
YS

WW FTase

1

1

2.1 x 103 ± 200

YL Variant

9.8 x 104

1.2 x 105

FL Variant

9.6 x 104

1.3 X 105
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Fig 5.. A Lineweaver
Lineweaver-Burk plot of the FL variant with dansyl-GCVYS.
GCVYS. The
plot fits a linear model corresponding to the inverse of the Michaelis-Menten
Michaelis
equation from which the Kcat/KM value can be calculated. This reaction was
run with 20 nM enzyme.

Variant
ariant Resistance to FPTII Inhibitor
Inhibitor. During thee active site titrations of the
purified WT FTase and FTase variants, wildtype-FTase reaches a clear saturation
point indicative of peptide binding saturation while the FL and YL FTase variants
do not. This lack of saturation suggests that the FL and YL active site mutations
interfere with formation of the initial FTase*FPTII complex or the formation of
the FTase*FPTII*peptide ccomplex. To determine if FPTII inhibitor binding is
affected in the YL and FL FTase variants, the inhibition constant (Ki) for the
FPTII inhibitor was measured with each variant with either dansyl-GCVLS
dansyl
or
dansyl-GCVYS peptide substrates
substrates. Results are shown in Table 3. The increased

20

Ki values of FPTII with the variants and the dansyl-CVLS substrate as compared
to wildtype-FTase suggest a decreased affinity of FPTII inhibitor for FTase,
which is consistent with our results. The Ki of FPTII of the FL variant with CVYS
is considerably lower than the Ki of FPTII of the FL variant with CVLS. This
suggests that inhibitor resistance maybe substrate dependent.

Table 3. Ki values of FPTII inhibitor with wildtype FTase, FL FTase and YL
FTase with the peptides dansyl-CVLS and dansyl-CVYS
Enzyme

Ki (uM)
LS

Ki (uM)
YS

WW FTase

0.3 ± 0.2

NA

YL Variant

5.1 ± 5.3

NA

FL Variant

13.5 ± 15.6

0.23 ± 0.042

The increased resistance to the competitive inhibitor FPTII in the presence of a
saturating amount of FPP suggests either a decrease in the binding affinity of
FPTII and/or an increase in the binding affinity of FPP. The values of KM of FPP
with the variants, calculated from FPP titrations, are reported in Table 4. The
decreased KM of FPP with the variants as compared to wildtype-FTase is
consistent with the variants exhibiting tighter FPP binding, which could lead to
less effective competitive inhibitor by FPTII.
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Table 4. The KM values of FPP with wildtype FTase, W102F W106L FTase and
W102Y W106L FTase with dansyl-CVLS
Enzyme

KM (M)
LS

WW FTase

7.56 ± 3.0

YL Variant

0.92 ± 0.37

FL Variant

1.0 ± 0.17

Reactivity of Selected Variants in vivo. To examine farnesylation activity of the
W102F W106L and W102Y W106L variants in vivo, pCAF2 vectors containing
the mutants were transfected into HEK293T cells. The pCAF2 vectors
allowed for co-expression of a variant FTase along with a fusion protein tagged
with a red fluorescent protein (TagRFP) at its N-terminal. The fusion protein
comprises of the upstream sequence H-Ras (-KLNPPDESGPGCMSC-) and either
–GCVLS or GCVYS at its C-terminal. Farnesylation activity was monitored by
the localization of the fusion protein as determined from the distribution of
fluorescence.
The cells were characterized as “Localized” where the reporter protein is
located mainly to the plasma membrane, “Mixed” where the reporter protein
located at cellular membranes and throughout the cytosol and “Diffuse” where the
reporter protein is located throughout the cytosol (Figure 6). In the vector with
wildtype FTase and TagRFP-CVLS, 50% of the cells exhibit localized
fluorescence and 50% display mixed fluorescence. Changing the C-terminal
sequence of the fluorescent protein to CVYS in the presence of wild-type FTase
(WW CVYS) leads to a complete loss of “localized” fluorescence, with 97% of
22

cells exhibiting diffuse
iffuse fluorescence and 3% mixed fluorescence.. Introduction of
the FL FTase
ase variant in the presence of TagRFP-CVYS
CVYS increased the number of
cells displaying mixed ffluorescence,
luorescence, but did not lead to localized fluorescence
(Figure 7). These results indicate that the FL FTase variant is active within the
cell.

A

B

C

Fig 6. Examples of TagRFP fluorescence localization in HEK293T cells: A. Diffused
B. Mixed C. Localized

Fig 7. Fluorescent Localization of pCAF2 XX CVa2S in HEK293T cells.

23

DISCUSSION
The W102β and W106β residues of FTase play the key roles in recognizing the
a2 residue, one of the determinants of peptide selectivity by FTase. The two
developed FTase variants, W102F W102L and W102Y W106L, exhibit
farnesylation activity with the CVLS and CVYS peptide. The chosen target
peptide, CVYS, differs from the native substrate CVLS in that the amino acid at
its a2 position is larger while remaining hydrophobic. The two FTase variants
selected in this work for their increased reactivity with the CVYS peptide both
contain a tryptophan to leucine mutation at position 106β, which maintains
hydrophobic character at this position while reducing amino acid size. Mutations
observed at position 102β keep an aromatic amino acid at this position while also
reducing amino acid size. These mutations suggest that increasing reactivity with
the CVYS peptide requires relaxation of steric discrimination within the FTase
active site pocket while preserving hydrophobic character in the a2 binding
pocket. The change in substrate selectivity observed in this work demonstrates the
flexibility of the FTase active site and suggests that FTase selectivity is easily
tunable with directed mutations at the W102β and W106β residues.
Notably, the FTase variants are capable of accelerating reactions with the –
GCVYS peptide ~100 fold without losing reactivity with –GCVLS. This
conservation of activity with GCVLS with W102β and W106β mutants has been
observed in previous studies (7). The reactivity of the W102F W102L and
W102Y W106L variants with CVLS reconfirm that the W102β and W106β
residues are not vital in selecting for the natural substrate for prenylation. Instead,
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the residues at the 102β and 106β positions select against substrates on the basis
of size and polarity (7).
Bioengineered prenylation pathway. By mutating two residues within FTase,
FTase variants with expanded substrate selectivity were developed. Studies of the
enzymes involved in latter steps of the prenylation pathway have been restricted
by the limited substrates of FTase. The novel variants identified in this study that
can prenylate substrates with the CVYS as well as the CVLS motif lessens this
constraint and can serve as tools for future prenylation studies.
In addition, studies of any single prenylation pathway within a cell have been
limited because isolation of a single pathway was not possible; inhibitor treatment
of FTase or any succeeding enzyme knockouts every farnesylation pathway
within the cell. The unexpected finding that the novel variants are resistant to the
inhibitor FPTII makes them all the more powerful as tools as they potentially can
be implemented in a single specific prenylation pathway in in-vivo studies without
the background of other prenylation pathways.
In conclusion, the W102β and W106β residues of FTase are easily tunable for
controlled substrate selectivity. Variant FTases/fusion protein pairs are also
powerful tools for studying prenylation modifications downstream of FTase
farnesylation. This will ultimately lead to a better understanding of the
prenylation pathway inhibitors effective against prenylate Ras-protein diseases
such as cancer and cardiovascular disease.
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Capstone Summary
Posttranslational modification, a critical step in protein biosynthesis, plays
an essential role in regulating protein structure and function. Within a cell,
posttranslational modifications are carried out by enzymes, catalytic biological
molecules that accelerate the rate of chemical reactions. Protein prenylation is an
important posttranslational modification required for the proper localization and
function of many eukaryotic proteins. In the first step of the prenylation pathway,
the enzyme farnesyltransferase (FTase) catalyzes the addition of a fifteen-carbon
prenyl group to the cysteine of the “Ca1a2X” C-terminal sequence of a substrate
protein. However, the interactions that lead to selectivity within the Ca1a2X
sequence are still not well defined and FTase is proposed to modify a pool of
substrates numbering more than one hundred.
Prenylated proteins are involved in vital cell signaling transduction
pathways that control cell growth and differentiation, with these proteins linked to
diseases including cancer and cardiovascular disease. Understanding how protein
prenylation affects cellular health requires us to identify which proteins are
prenylated and then characterize the impact of prenylation pathways
modifications on protein structure and function. We seek to understand the
interactions in the FTase active site that engender substrate selectivity.
In this study, we developed a library of ~400 FTase variants using a
previously generated FTase plasmid library wherein the codons for the two active
site amino acids, W102β and W106β, have been randomized. Codons, specific
sequences of three nucleotides, determine the amino acid that is translated into the
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peptide; thus, randomized codons at position W102β and W106β will result in
random amino acids at those positions. 94 of the variants were screened for
prenylation activity with three target peptides that bear Ca1a2X sequences that are
less reactive than native FTase substrates such as Ras (-CVLS) in parallel to the
natural substrate CVLS serving as a positive control. The peptide substrates were
labeled with a dansyl group to allow monitoring of peptide prenylation activity by
changes in dansyl fluorescence.
Two variant FTases that exhibited prenylation activity with the CVYS
target peptide were isolated from this screen. The mutated vectors were sequenced
and subsequently isolated and transformed into a strain of E. coli cells that is able
to express the FTase protein. The protein was purified by ion exchange Fast
Protein Liquid Chromatography (FPLC), a technique used to separate proteins by
charge.
Following purification, we characterized their reactivity with the
associated peptide targets to investigate how the mutations we observe lead to
changes in substrate selectivity. This included measuring peptide substrate
binding affinities, reaction velocities in the presence of both saturating and
subsaturating peptide concentrations, and the maximum rate for substrate turnover
by the selected FTase variants. We also tested the variants’ resistance to the
highly selective and potent inhibitor of wildtype FTase, FPTII.
In addition, to determine if the selected FTase variants exhibit biologically
relevant levels of prenylation activity, we assessed the ability of these variants to
prenylate a target fluorescent protein within a mammalian cell. Prenylation of the
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target protein leads to protein localization to cellular membranes, which can be
monitored by fluorescence microscopy. By co-expressing the given FTase variant
with a fluorescent protein terminating the peptide sequence used to select the
FTase variant, we determine if each variant is active enough to prenylate the
target protein leading to a change from diffused to localized fluorescence.
These studies will ultimately lead to a better understanding of the
selectivities and substrates for wildtype FTase. By mutating two residues within
FTase, we have developed FTase variants with expanded substrate selectivity.
The alteration in substrate selectivity observed in our variants suggests that FTase
selectivity may depend on a small number of “tunable” active site contacts. Our
work provides insight into how this multispecific enzyme recognizes its pool of
substrates and will also aid in identifying additional FTase substrates. Studies of
the enzymes involved in latter steps of the prenylation pathway have been
restricted by the limited substrates of FTase. The novel variants identified in this
study that can prenylated substrates with the CVYS as well as the CVLS motif
lessens this constraint and can serve as tools for future prenylation studies. The
unexpected finding that the novel variants are also resistant to the inhibitor FPTII
makes them all the more powerful as tools as they can be implemented in a single
specific prenylation pathway in in vivo studies without the background of other
prenylation pathways.
In addition, the characterization of FTase substrate recognition derived
from my research will provide insight for the development of better FTase
inhibitors, an active area of drug research that is currently hindered because the
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specific protein targets of FTase are unknown. FTase inhibitors have been
designed and have been proven effective in the treatment of prenylated Rasprotein-related diseases such as various forms of cancer by suppressing
angiogenesis and inducing apoptosis.
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